Cargando…

BRCAness as a prognostic indicator in patients with early breast cancer

BRCAness is defined as a phenotypic copy of germline BRCA mutations, which describes presence of homologous recombination defects in sporadic cancers. We detected BRCAness by multiplex ligation-dependent probe amplification (MLPA) and explored whether BRCAness can be used as a predictor of prognosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Lei, Matsunaga, Yuki, Tsurutani, Junji, Akashi-Tanaka, Sadako, Masuda, Hiroko, Ide, Yoshimi, Hashimoto, Rikako, Inuzuka, Mayuko, Watanabe, Chie, Taruno, Kanae, Sawada, Terumasa, Okuyama, Hiromi, Ata, Arisa, Kuwayama, Takashi, Nakayama, Sayuka, Tonouchi, Yumi, Nakamura, Seigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713365/ https://www.ncbi.nlm.nih.gov/pubmed/33273622 http://dx.doi.org/10.1038/s41598-020-78016-8

Ejemplares similares

Diagnostic performance of dedicated breast positron emission tomography
por: Hashimoto, Rikako, et al.
Publicado: (2022)

BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ
por: Liu, Yan, et al.
Publicado: (2019)

Optimal Breast Density Characterization Using a Three-Dimensional Automated Breast Densitometry System
por: Yoshida, Reika, et al.
Publicado: (2021)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
por: Kosaka, Yoshimasa, et al.
Publicado: (2020)

Examining the effectiveness of a deep learning-based computer-aided breast cancer detection system for breast ultrasound
por: Fujioka, Tomoyuki, et al.
Publicado: (2023)

Magnetically Guided Localization Using a Guiding-Marker System(®) and a Handheld Magnetic Probe for Nonpalpable Breast Lesions: A Multicenter Feasibility Study in Japan
por: Kurita, Tomoko, et al.
Publicado: (2021)

BRCAness in prostate cancer
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2019)

The BRCAness Landscape of Cancer
por: Guo, Maoni, et al.
Publicado: (2022)

AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample
por: Yoshida, Reiko, et al.
Publicado: (2021)

The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan
por: Murakami, Wakana, et al.
Publicado: (2019)

BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
por: Wysham, Weiya Z., et al.
Publicado: (2012)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge
por: Caeiro, Cláudia, et al.
Publicado: (2022)

Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness
por: Darbeheshti, Farzaneh, et al.
Publicado: (2022)

Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X
por: Yoshida, Reiko, et al.
Publicado: (2019)

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness
por: Tutt, A
Publicado: (2018)

Development of a novel BRCAness score that predicts response to PARP inhibitors
por: Oshi, Masanori, et al.
Publicado: (2022)

Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome
por: Kaneyasu, Tomoko, et al.
Publicado: (2020)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
por: Lin, Po‐Han, et al.
Publicado: (2020)

DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma
por: Barenboim, Maxim, et al.
Publicado: (2021)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells
por: Chirshev, Evgeny, et al.
Publicado: (2021)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells
por: Matsunaga, Yuki, et al.
Publicado: (2021)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors
por: Zhang, Chao, et al.
Publicado: (2023)

Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy
por: Mori, Miki, et al.
Publicado: (2019)

Exploratory Study of Superparamagnetic Iron Oxide Dose Optimization in Breast Cancer Sentinel Lymph Node Identification Using a Handheld Magnetic Probe and Iron Quantitation
por: Taruno, Kanae, et al.
Publicado: (2022)

Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies
por: Stok, Colin, et al.
Publicado: (2021)

Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype
por: Jeong, Keun-Yeong, et al.
Publicado: (2021)

miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype
por: Tommasi, Stefania, et al.
Publicado: (2016)

STAT3 imparts BRCAness by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes
por: McIntosh, Michael T., et al.
Publicado: (2020)

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests
por: Meijer, Titia G., et al.
Publicado: (2022)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
por: Mori, Hitomi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lmbrm57l4tjp333s59jlch3muk